E-resources
-
Loebel, Antony; Cucchiaro, Josephine; Sarma, Kaushik; Xu, Lei; Hsu, Chuanchieh; Kalali, Amir H.; Pikalov, Andrei; Potkin, Steven G.
Schizophrenia research, April 2013, Volume: 145, Issue: 1-3Journal Article
This study was designed to evaluate the short-term efficacy and safety of once-daily lurasidone (80mg/day and 160mg/day) in the treatment of an acute exacerbation of schizophrenia. Participants, who were recently admitted inpatients with schizophrenia with an acute exacerbation of psychotic symptoms, were randomly assigned to 6weeks of fixed-dose, double-blind treatment with lurasidone 80mg (n=125), lurasidone 160mg (n=121), quetiapine XR 600mg (QXR-600mg; n=119; active control included to test for assay sensitivity), or placebo (n=121), all dosed once daily in the evening. Efficacy was evaluated using a mixed-model repeated-measures analysis of the change from Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) total score (the primary efficacy measure) and Clinical Global Impressions severity (CGI-S) score (the key secondary efficacy measure). Treatment with both doses of lurasidone or with QXR-600mg was associated with significantly greater improvement at Week 6 on PANSS total score, PANSS positive and negative subscale scores, and CGI-S score compared with placebo. The endpoint responder rate (≥20% improvement in PANSS total score) was higher in subjects treated with lurasidone 80mg (65%; p<0.001), lurasidone 160mg (79%; p<0.001), and QXR-600mg (79%; p<0.001) compared with placebo (41%). The proportion of patients experiencing ≥7% weight gain was 4% for each lurasidone group, 15% for the QXR-600mg group, and 3% for the placebo group. Endpoint changes in levels of cholesterol, triglycerides, and low-density lipoprotein (LDL) cholesterol were comparable for both lurasidone groups and placebo, while the QXR-600mg group showed a significant median increase compared with the placebo group in levels of cholesterol (p<0.001), LDL cholesterol (p<0.01), and triglycerides (p<0.05). Lurasidone 80mg and 160mg doses administered once-daily in the evening, were safe and effective treatments for subjects with acute schizophrenia, with increased response rates observed at the higher dose. Dose-related adverse effects were limited, and both doses were generally well-tolerated.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.